Intensive blood pressure management during breast cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates whether an intensive approach to managing high blood pressure is safer and more effective than standard treatment during breast cancer therapy. It focuses on patients undergoing anthracycline-based chemotherapy and aims to lower blood pressure levels while reducing the risk of cardiotoxicity. The trial will measure blood pressure, conduct echocardiograms, and assess quality of life, without testing specific medications. Participants will be monitored closely to evaluate the effectiveness of the treatment strategy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Female assigned at birth
* Biopsy proven breast cancer (stage I-IV)
* Treatment with therapy anthracycline-based chemo (with or without HER2-targeted therapy), with \>/= 2 cycles of anthracycline chemotherapy planned.
* SBP ≥130 mm Hg
* Willing and able to comply with the requirements of the protocol.
* Participant must have and be willing to use their bluetooth enabled wifi or cellular mobile device
* (For participants in the CPET cohort): Able to complete an acceptable baseline CPET, in the absence of high-risk ECG findings or other inappropriate response to exercise as determined by the PI, as defined by any of the following criteria:

  * Achieving a plateau oxygen consumption, concurrent with an increase in power output;
  * A respiratory exchange ratio ≥ 1.10;
  * Attainment of maximal predicted heart rate, as defined by a peak heart rate within 10bpm of the age predicted maximal heart rate (220 - Age\[years\]);
  * Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.

Exclusion Criteria:

* eGFR \< 30 ml/min/1.73m2 (based upon Cockcroft-Gault, etc.)
* Individuals with arm circumference too large to allow accurate BP measurement with available BP devices
* Inability to accurately measure blood pressure in at least one arm (e.g., bilateral upper extremity lymphedema)
* Cardiac comorbidity, including any of the following:

  * Acute coronary syndrome within 3 months prior to randomization.
  * Symptomatic heart failure (NYHA class III/IV) within past 6 months
  * History of stroke
  * Cardiac transplantation
* Other medical disorder or condition that in the opinion of the investigator would impair the subject's ability to participate or adhere to study interventions
* (For participants in the CPET cohort): Subjects must not have any of the following absolute contraindications to cardiopulmonary exercise testing:

  * Acute myocardial infarction (within 30 days of any planned study procedures),
  * Unstable angina
  * Uncontrolled arrhythmias causing symptoms or hemodynamic compromise,
  * Symptomatic severe aortic stenosis
  * Recurrent syncope
  * Active endocarditis
  * Acute myocarditis or pericarditis
  * Acute pulmonary embolus or pulmonary infarction (within 3 months of any planned study procedures)
  * Thrombosis of lower extremities (within 3 months of any planned study procedures)
  * Suspected dissecting aneurysm
  * Uncontrolled asthma
  * Pulmonary edema
  * Room air desaturation at rest ≤85%
  * Respiratory failure
  * Acute noncardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (i.e., infection, renal failure, thyrotoxicosis)
  * Mental impairment leading to inability to cooperate.

Where it's running

• Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen (Limited Protocol Activities)
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester (Limited Protocol Activities)
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Anthony Yu, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Anthony Yu, MD
• Email: yua3@mskcc.org
• Phone: 212-639-7932

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• Exercise and fitness program for breast cancer survivors to improve heart health

  This study tests whether a special exercise and yoga program can help breast cancer survivors over 60 improve their heart health and physical fitness after treatment.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06595147

• Monitoring heart health in breast cancer patients receiving trastuzumab

  This study is testing if measuring a specific blood marker can help track heart health in breast cancer patients getting trastuzumab treatment, to see if it can replace traditional heart scans.

  Recruiting Vastra Gotaland Region · Gothenburg · NCT06340516

• Using Nicotinamide Riboside to Prevent Heart Problems in Breast Cancer Patients

  This study is trying to see if a supplement called nicotinamide riboside can help prevent heart problems in women with metastatic breast cancer who are receiving certain chemotherapy treatments.

  Recruiting Phase 2 University Hospital, Akershus · Lørenskog, Akershus · NCT05732051

• Global Cardio Oncology Registry

  This study is collecting health information from cancer patients around the world to see what factors might increase their risk of heart problems caused by cancer treatments.

  Recruiting The Cleveland Clinic · Weston, Florida · NCT05598879

• Using Sacubitril/Valsartan to prevent heart damage in breast cancer treatment

  This study is testing if the medication Sacubitril/Valsartan can help protect the hearts of women undergoing treatment for breast cancer from damage.

  Recruiting at 3 sites Phase 4 Silesian Centre for Heart Diseases · Opole, Opole Voivodeship and 3 other locations · NCT05465031

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.